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Ehlers–Danlos syndrome (EDS) is a prototypic connective
tissue disorder with characteristic skin and joint involvement
(Uitto et al, 2003). The cutaneous features include loose and
fragile skin, poor wound healing, bruising tendency, and
the scars are characteristically atrophic, often resembling
‘‘cigarette paper’’. In addition, there are a number of extra-
cutaneous manifestations, including hyperextensible joints
with propensity to dislocations, and in certain subtypes of
EDS, fragility of blood vessels, gastrointestinal tract and
uterus can result in catastrophic complications. The first
clinical description detailing this disorder dates back to
1892 by Dr. Tschernogobow, a Russian dermatologist, and
subsequently, Drs. Ehlers and Danlos, Danish and French
dermatologists, respectively, expanded on the systemic
nature of this condition. The genetic nature of EDS was
recognized in 1949, and its clinical manifestations were
subsequently suggested to result from defects in the
collagen ‘‘wicker work’’. The genetic heterogeneity of EDS
was established in the 1960s, and the first molecular
defects in collagen biosynthetic pathways were delineated
in patients with EDS in 1972 (McKusick, 1972).
Traditionally, EDS has been subdivided into 11 distinct
variants (types I–XI), based on clinical observations, mode
of inheritance, and/or molecular characterization. A con-
sensus conference held in 1997 (Villefranche), however,
proposed a revised nosology, which recognizes six distinct
subtypes (Beighton et al, 1998). In fact, several previously
described variants, some of them exceedingly rare and not
well-defined, were excluded from the EDS category.
The molecular basis of the major forms of EDS is now
well-established, and the clinical manifestations are based
primarily on mutations in the genes encoding collagen
polypeptide subunits or enzymes that modify the primary
collagen translation products. Collagen consists of a family
of proteins, and there are as many as 27 distinct vertebrate
collagens (types I–XXVII) (Myllyharju and Kivirikko, 2004).
Each collagen molecule is composed of three a-chain
subunits, which can be identical in homotrimers, or consist
of two or three different kinds of polypeptides in hetero-
trimers. Thus, there are over 40 different genes encoding
the distinct a-chains that are synthesized as precursor
polypeptides, pro-a-chains. These polypeptides are hy-
droxylated and glycosylated in reactions catalyzed by specific
enzymes, three of the pro-a-chains then fold into the
characteristic triple-helical conformation, and the collagen
molecules are secreted into the extracellular milieu where
they undergo proteolytic processing, fiber assembly, and
formation of stabilizing inter- and intra-molecular crosslinks.
In different forms of EDS, specific mutations have been
identified in type I, III, and V collagen polypeptides, as well
as in two enzymes that modify the collagen molecules (Uitto
et al, 2003). These molecular defects explain the connective
tissue weakness and ultrastructural abnormalities in col-
lagen fibrils. Specifically, as demonstrated by transmission
electronmicroscopy, the collagen fibrils show considerable
variability in their diameter, and although individual fibrils
can be unusually large with irregular contour, the density of
collagen fibrils is often reduced. Thus, EDS has been
considered as a disease of collagen.
Evidence of molecular heterogeneity beyond the col-
lagens was initially presented by observations on a patient
with adrenal hyperplasia and a classical form of EDS, who
was found to harbor a 30-kb contiguous gene deletion on
the short arm of chromosome 6 (Burch et al, 1997). The
deleted interval contained both the CYP21 gene that
encodes steroid 21-hydroxylase and the TNX gene, which
encodes tenascin-X, a connective tissue protein develop-
mentally associated with collagen fibrils. It was subse-
quently demonstrated by immunofluorescence of the skin of
this and similar patients that they were lacking tenascin-X,
and their serum contained essentially undetectable levels of
this protein. The suggestion that tenascin-X is directly
involved in the pathogenesis of EDS was subsequently
confirmed by demonstration of null mutations in both alleles
of TNX, and the mutations in these patients were clearly
autosomal recessive (Schalkwijk et al, 2001). The clinical
features in these patients were similar to those of the
classical autosomal dominant type of EDS, except that the
tenascin-X deficient patients lack atrophic scars and wound
healing is not consistently delayed, findings characteristic of
classic EDS. The pathoetiologic role of tenascin-X has been
further confirmed by the development of TNX null mice,
which recapitulate many of the features of patients with
tenascin-X deficiency (Mao et al, 2002).
In this issue, Zweers et al (2004) have examined five
TNX-deficient individuals for changes in dermal connective
tissue, which consists of four major groups of extracellular
matrix components, viz., collagen, the elastic fibers, non-
collagenous glycoproteins, and glycosaminoglycan/proteo-
glycan macromolecules. The principal fiber networks
consist of collagen and elastin, which interact with non-
collagenous glycoproteins, such as elastin-associated
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microfibrillar proteins (MFAPs) and glycosaminoglycan/
proteoglycans. The supramolecular organization of these
extracellular matrix components, as well as their interac-
tions with cellular components of the connective tissue,
have previously allowed identification of critical metabolic
and structural features that are prerequisites for normal
physiological function of the skin. Zweers et al (2004) now
report that, in addition to previously reported reduction in
dermal collagen, there are major abnormalities in elastic
fibers and associated microfibrils in the dermis of these
patients. The elastic fibers are fragmented, clumped, and
devoid of microfibrils. Based on these observations, the
authors suggest that abnormality in elastic fibers contri-
butes to the clinical phenotype, and they put forward a
proposal that tenascin-X may serve as an ‘‘organizer of
connective tissue assembly’’.
The authors’ interpretation raises a couple of questions.
First, all skin biopsies were obtained from TNX-deficient
patients with the age range of 32–56 years. Since these
patients are reported to have clinical findings since early
childhood, could the changes in elastic fibers just be
secondary to overall instability of the connective tissue due
to collagen abnormalities? In this context, it should be
noted that elastin abnormalities have been demonstrated in
the skin of EDS patients with clear cut collagen defects
and presumably no tenascin-X deficiency. It should also
be noted that although fibrillin-1, a major non-collagenous
glycoprotein associated with the elastic fiber network, was
deficient in the skin of the patients studied by Zweers et al
(2004), the primary synthesis of fibrillin-1 by TNX-deficient
fibroblasts was not altered.
Another puzzling question relates to the fact that the
collagen density was reported to have been reduced to
about 40% of the control, yet the thickness of the dermis
was unaltered. Considering the fact that collagen comprises
 80% of the extracellular matrix of the dermis, one would
expect significant atrophy, unless there is substitution of
collagen by some other material. The authors studied the
presence of glycosaminoglycans/proteoglycans with spe-
cific histopathologic and immunohistochemical stains. No
difference in the negatively charged polysaccharides or in
the distribution of decorin could be detected between
tenascin-X deficient and normal skins. The authors suggest
that this discrepancy between reduced collagen content
and normal skin thickness could possibly be explained by
edema, a suggestion that clearly does not conform with
the clinical observation of soft and velvety skin in these
patients.
Collectively, the data reported by Zweers et al (2004)
confirm that tenascin-X deficiency can result in connective
tissue abnormalities, which manifest as classical EDS with
autosomal recessive inheritance. These findings add to the
molecular complexity of EDS beyond the collagens, but
they also provide a diagnostic test through serum assay of
tenascin-X, helpful in subclassification of EDS as well as
providing information on the mode of inheritance with
implications for genetic counseling.
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